All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and dual-energy CT will be performed first for high-risk screening subjects, and dual-energy CT will be performed first for the high-risk group to record dual-energy CT examinations of those suspected of nasopharyngeal carcinoma, and then endoscopy was performed on the high-risk group to record those suspected of nasopharyngeal carcinoma under endoscopy, and finally biopsies were taken for positive lesion sites indicated by dual-energy CT and suspicious lesion sites found by endoscopy to clarify the diagnosis.
Subject residents in Zhongshan City
Subject has no medical record of nasopharyngeal carcinoma
Subject is able to comprehend, sign, and date the written informed consent document to participate in the study
Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study
Subject has heavy cardiovascular, liver or kidney disease
Subject has contraindications to nasopharyngeal endoscopy
Subject has contrast media allergy